Biofarma

Italian family holding for the Germani family's Biofarma Group, a CDMO producing 250M+ pharma units yearly across Italy, France, and the US.

Biofarma

Biofarma S.r.l. is the Italian holding company for the Germani family's pharmaceutical interests, centered on the Biofarma Group — a contract development and manufacturing organization (CDMO) built from a single facility in Mereto di Tomba, Udine. The group expanded via acquisitions, including the 2017 purchase of US-based Purity Laboratories and the 2020 acquisitions of Valpharma and Enpharma, consolidating a pan-European manufacturing footprint. Founder and Chairman Dino Germani led the firm from a regional generics player into an international nutraceutical and pharmaceutical outsourcer. The firm deploys capital directly into manufacturing capacity — softgels, sachets, tablets, and sterile liquids — serving third-party pharma brands rather than developing proprietary drugs. Manufacturing sites span Italy, France, and the United States. The group produces over 250 million units annually across 1,200 product formulations, with a client base reaching 40 countries. The strategy is capacity-led and geographically diversified, with the US market representing a growing share following the Purity Labs acquisition and a reported 2022 minority investment from private equity firm Bridgepoint (per Reuters, 2022) to accelerate international growth. Though team size and AUM are not publicly disclosed, the group reportedly generates revenues exceeding €200 million (per Il Sole 24 Ore, 2023). The Germani family remains the controlling shareholder, with Bridgepoint Development Capital acquiring a minority stake in 2022 to support the CDMO platform's international expansion. The firm does not operate adjacent philanthropic foundations publicly tied to the holding structure, nor does it manage external capital. Biofarma is distinct among Italian family offices in that it resembles an industrial holding company more than a financial allocator. The wealth is inseparable from the operating business — there are no disclosed fund commitments, co-investment clubs, or liquid portfolio strategies. The structure is a single-family industrial group with a private equity minority partner, making it inaccessible to external allocators and purely self-directed in deployment.

General information

Firm type

Single Family Office

Year founded

—

AUM

Undisclosed

Location

Region

Europe

Country

Italy

City

—

Corporate office

Italy

Who controls investment decisions at Biofarma S.r.l.?

Dino Germani, the founder and chairman, has historically directed strategy alongside family members. The 2022 minority sale to Bridgepoint Development Capital introduced an external governance partner, but the Germani family retains majority control and operational oversight of all manufacturing expansion decisions.

Does Biofarma function as a conventional family office or an operating company?

It operates almost entirely as an industrial holding company. The firm's capital is deployed into manufacturing plants, equipment, and acquisitions that extend its CDMO capabilities — not into a diversified financial portfolio. There are no disclosed fund commitments, direct venture investments, or liquid securities allocations.

How is Biofarma Group related to the Germani family's wealth?

The group is the primary vessel for the family's industrial wealth. Drug manufacturing generated the fortune, and the holding company reinvests earnings directly into expanding production capacity and geographic reach. No separate family office entity managing liquid assets has been publicly identified.

What is Biofarma's known posture on co-investments alongside external GPs?

None publicly disclosed. The 2022 Bridgepoint deal was a direct minority equity sale, not a co-investment fund structure. There is no record of Biofarma participating as an LP in third-party private equity or venture funds.

What geographies does Biofarma's manufacturing cover?

The group operates production sites in Italy (Mereto di Tomba and other locations), France (via acquisitions), and the United States (Purity Laboratories, acquired 2017). Products reach clients in approximately 40 countries, with Europe and North America as the primary end markets.

Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: Jun 3, 2026. Continuous refresh with full update cycles at least every 30 days.